High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT00186394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Study identification
- NCT ID
- NCT00186394
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 61 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2000
- Primary completion
- Nov 30, 2006
- Completion
- Nov 30, 2006
- Last update posted
- Jul 26, 2010
2000 – 2006
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Lymphoma, Non-Hodgkin trials
Other public records listing Lymphoma, Non-Hodgkin. Sorted by last update posted; newest first. Not a recommendation.
- NCT07519772: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) Recruiting
- NCT07082803: TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas Recruiting
- NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL Active, not recruiting
- NCT07607925: A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL Not yet recruiting
- NCT07652580: Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Recruiting
- NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00186394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2010 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00186394 live on ClinicalTrials.gov.